... immunizations are being conducted, with several additional passive tau antibody trials likely to be initiated in the near future for Alzheimer's disease and other tauopathies. Because tau pathology correlates better with the degree of dementia than amyloid-β (Aβ) pathology, greater clinical efficacy may...

...Pawel Tacik; Monica Sanchez-Contreras; Rosa Rademakers; Dennis W. Dickson; Zbigniew K. Wszolek Background: Tauopathies are a group of neurodegenerative disorders characterized by the pathological accumulation of hyperphosphorylated and insoluble tau protein within neurons and glia. Although most...

... attractive target once cognitive impairments are evident, while Aβ therapies may be better suited for the presymptomatic phase of the disease. Over 12 years ago, we initiated a tau immunotherapy program, seeking to alleviate the functional impairments associated with tau lesions in tauopathies. We have...

...Norbert Zilka; Zuzana Stozicka; Martin Cente; Zuzana Kazmerova; Branislav Kovacech; Michal Novak Background: Neurodegeneration induced by misfolded tau protein and neuroinflammation represent the major hallmarks of human tauopathies including Alzheimer’s disease (AD). While tau driven...

...Kurt A. Jellinger Background: Proteinopathies are a heterogenous group of neurodegenerative disorders, characterized by intra- and extracellular accumulation of abnormal filament proteins. Objective: To describe the neuropathology of specific forms of tauopathies and synucleinopathies, the overlap...